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amyloidosis.Fig 1. Squamous cell carcinoma identified after multiple
biopsy specimens of poorly healing area over leftE
pidermolysis bullosa (EB) consists of a het-
erogeneous group of autosomal dominant or
recessive disorders, characterized by epithe-
lial fragility.1 In dystrophic EB, patients have a
genetic defect in the gene encoding collagen VII,
COL7A1. Generalized severe recessive dystrophic EB
(RDEB) is characterized by large, flaccid bullae
present at birth with healing atrophic scars.2 RDEB
is associated with a high mortality and morbidity.
Although no definitive therapy exists, recent
advances in medical care have significantly in-
creased the survival of RDEB. This has exposed
complications not previously observed, including
secondary amyloidosis, which can have fatal out-
comes. Secondary amyloidosis, a rare complication,
has been scarcely reported in the literature to date,
usually solely affecting renal function. We report a
case of RDEB with amyloidosis, causing liver hy-
pertrophy and caput medusa.malleolus.CASE REPORT
A 25-year-old woman presented with a 2-month
history of gradual-onset right upper-quadrant
abdominal pain, with associated abdominal
distension and dark urine. She was born to non-
consanguineous parents, and diagnosed at birth
with RDEB. She had inherited 2 heterozygous
deletion mutations in the COL7A1 gene, c
[4918del] in exon 52 and [7634del] in exon 102,
predicting 2 frameshift mutations, p. [Gly1640fs]
and [Gly2545fs], with downstream premature
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fluorescence mapping.
Blistering was extensive from early infancy,
causing cutaneous scarring and mitten deformities
of hands and feet. She developed associated compli-
cations, including squamous cell carcinoma (Fig 1),
dental caries, esophageal strictures, anal fissures,
osteoporosis, anemia, hypogonadotropic hypogo-
nadism, and bilateral inferior exposure keratopathy.
Previous procedures included surgeries to correct
hand contractures, right lower lid ectropion repair,JAAD Case Reports 2015;1:337-9.
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Fig 2. Histology of liver biopsy specimen showing pos-
itive immunostain for amyloid A protein (A). B, High-
power view; black arrow indicates compressed sinusoids.
C, Low-power view; red arrows indicate obliterated
hepatocytes. (A-C, Original magnifications: A and B,
3400; C, 3100.)
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Medications included long-standing phenytoin (50
mg) 3 times daily to aid wound healing, pantopra-
zole, cholecalciferol, estradiol/norethisterone, prega-
balin, tramadol, and oxycodone.
Physical examination revealed weight 27 kg,
massive hepatomegaly with caput medusa, and right
upper-quadrant tenderness. Investigations revealed
normochromic anemia (hemoglobin 8.5 g/dL), hy-
ponatremia (212 g/dL), hypoalbuminemia (2.1 g/
dL), creatinine 48 mol/L, and liver function test
results demonstrating a cholestatic picture (GGT 356
U/L, ALP 443 U/L, alanine transaminase 6 U/L,
aspartate transaminase 20 U/L, bilirubin 0.1 mg/dL,
international normalized ratio 1.4). Total globulins
were significantly decreased (9.5 g/dL). Chronic
liver disease screen produced negative findings
(antinuclear antibody, SMA, anti-LKM, hepatitis B,
hepatitis C, alpha-antitrypsin, and ceruloplasmin).
Liver ultrasound revealed gross hepatomegaly with
‘‘starry-sky’’ appearance, and no common bile duct
dilatation or gallstones.
Over 6 months, her hepatomegaly worsened.
Further investigation revealed negative antimito-
chondrial antibody, anti-M2, GP210 and SP100,
paraprotein, urine Bence-Jones protein, and
angiotensin-converting enzyme level. Total IgG
was elevated (6.5 g/dL), and other immunoglobu-
lins were normal.
Liver biopsy specimen demonstrated florid
secondary amyloidosis (type AA), without fibrosis
(Fig 2). The liver parenchyma was extensively
obliterated by the deposition of homogenous,
eosinophilic material, compressing sinusoids, dis-
torting the architecture, and destroying hepato-
cytes. There were no portal tracts or fibrosis.
Immunostains for amyloid protein P and A showed
strong, diffuse staining. Laser capture microdissec-
tion and tandem mass spectrometry performed on
the liver biopsy demonstrated the amyloid forming
protein SAA2 as well as the amyloid associated
proteins ApoE, SAP, ApoA4, vitronectin, and clus-
terin, which was consistent with a diagnosis of AA
amyloidosis.
Further investigations for amyloidosis revealed
elevated serum amyloid A (34.8 mg/L), kappa light
chains (725 mg/L), and lambda light chains (274 mg/
L). Paraprotein was negative.
In light of the underlying EB and likelihood of
amyloidosis recurrence, hepatic transplantation was
not undertaken. The patient was monitored for signs
of hepatic decompensation. Over 2 years after biopsy
specimen, liver function test results remained stable,
and abdominal ultrasound unchanged. Massive ab-
dominal distension and pain remain problematic.Recently, 24-hour urine collection revealed pro-
tein/creatinine ratio greater than 300, and testing
demonstrated glomerular filtration rate adjusted for
body surface area 50.7 mL/min/1.73 m2, indicating
moderate renal impairment. As no other cause of
renal impairment was found, this was attributed to
renal amyloidosis. Because of the significant
morbidity associated with a renal biopsy, renal
amyloidosis has yet to be confirmed histologically.
DISCUSSION
Amyloidosis consists of a heterogeneous group of
disorders where normally soluble plasma proteins
are deposited in the extracellular space in an
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amyloidosis) results from the improper processing of
serum amyloid A protein, which cannot be broken
down beyond an 8.5-kd fragment labeled amyloid A
protein.
Recurrent, substantial elevations of serum amy-
loid A protein are necessary, but not sufficient, for
amyloidosis to develop. AA amyloidosis occurs in
chronic inflammatory diseases, where serum amy-
loid A protein concentration can increase greater
than 2000 mg/L during the acute-phase response.2
Although secondary amyloidosis is a known
complication of chronic dermatoses, only 11 sporadic
cases of RDEB complicated by secondary amyloid-
osis have been reported. Bourke et al3 described fatal
systemic amyloidosis in twin sisters with RDEB; in
both cases the amyloidosis was rapidly progressive,
leading to death. Mann et al4 reported a case of renal
amyloidosis, suggesting that renal involvement nega-
tively alters the course of EB. Dunnill et al5 reported
the first case of dominant dystrophic EBwith systemic
amyloidosis affecting spleen, liver, and kidney.
Csikos et al6 described a 25-year-old woman with
renal and pulmonary amyloidosis.
Kaneko et al1 reported a 17-year-old boy with
RDEB who died as a result of renal amyloidosis; a
subsequent retrospective study investigated the inci-
dence of renal amyloidosis in RDEB. They found that
7 of 9 patients with RDEB had nephropathy, however
the study was limited as renal biopsy specimens were
unable to be obtained for all patients.
There is no definitive treatment for RDEB.
Phenytoin is reported to be effective by inhibiting
the synthesis and secretion of collagenase from
dermal fibroblasts, and has been shown to increase
tolerance against trauma.2 Phenytoin may rarely
cause hepatotoxicity, occurring in less than 1% of
patients, usually within the first 6 weeks of treat-
ment.7 It has been associated with amyloidosis in 1
case report, with a 55-year-old man developing
renal amyloidosis with a monoclonal gammopathy,without coexisting multiple myeloma or lympho-
proliferative disorders.8 There have been no reports
in any condition associating phenytoin with AA
amyloidosis, hence we view it unlikely in this case.CONCLUSION
The prevalence of amyloidosis in EB may be
underappreciated as these patients have fragile skin,
they are susceptible to infections, and organ biopsy
is often difficult. As the clinical features of secondary
amyloidosis may be nonspecific, diagnosis is often
delayed. Hence, we recommend that physicians
consider the possibility of amyloidosis, both hepatic
and renal, in patients with dystrophic EB.
The authors acknowledge Lucie Monet, medical stu-
dent, at Flinders University, and David Astill, histopathol-
ogist, at Flinders Medical Center for their contribution.
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